



Attorney Docket No.: 6263.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anker Steen Jorgensen

Serial No.: 09/995,987

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

COPY OF PAPERS ORIGINALLY FILED

Confirmation No: 3030

For: Glucagon Antagonists/Inverse Agonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents Washington, DC 20231

Sir:

.]

I hereby certify that the attached correspondence comprising:

- 1. Response to Notice to File Missing Parts (in duplicate)
- 2. Copy of Notice to File Missing Parts
- 3. Executed Combined Declaration and Power of Attorney
- 4. Certified copy of Priority Application(s)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on January 17, 2002.

Sylvia Gonzalez

(name of person mailing paper)

(signature of person mailing paper)



Attorney Docket No.: 6263.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anker Steen Jorgensen

Serial No.: 09/995,987

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 3030

For: Glucagon Antagonists/Inverse Agonists

RESPONSE TO NOTICE TO FILE MISSING PARTS

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts dated December 11, 2001 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.

Applicants also enclose certified copy of Danish application no. PA 2000 01733 filed November 17, 2000, priority of which is claimed under 35 U.S.C. 119.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 17, 2002

Richard W. Bork, Reg. No. 36,459 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123

23650

PATENT TRADEMARK OFFICE





SOMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/995,987

11/16/2001 -

Anker Steen J_rgensen

6263.200-US

CONFIRMATION NO. 3030

FORMALITIES LETTER

Reza Green, Esq., 'OC000000007183255'

Novo Nordisk of North America, Inc. **Suite 6400** 405 Lexington Avenue New York, NY 10174-6401

Date Mailed: 12/11/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(I) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

09995337 02/06/2002 BAPRAHA1 00000005 141447

01 FC:105

130.00 CH

DOCKET (check off /)

BEST AVAILABLE COPY